These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38800235)

  • 61. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
    Rumpold H; Webersinke G
    Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
    Yamauchi T; Ueda T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
    Ma CC; Chai Y; Chen HL; Wang X; Gao Y; Hu WL; Xiang X
    J Int Med Res; 2020 May; 48(5):300060520919237. PubMed ID: 32366154
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation.
    Deng Q; Wang E; Wu X; Cheng Q; Liu J; Li X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 45(7):874-880. PubMed ID: 32879093
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
    Johansson B; Fioretos T; Mitelman F
    Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interphase FISH for BCR-ABL1 rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia.
    Balducci E; Loosveld M; Rahal I; Boudjarane J; Alazard E; Missirian C; Lafage-Pochitaloff M; Michel G; Zattara H
    Hematol Oncol; 2018 Feb; 36(1):344-348. PubMed ID: 28444777
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
    Kurzrock R; Kantarjian HM; Shtalrid M; Gutterman JU; Talpaz M
    Blood; 1990 Jan; 75(2):445-52. PubMed ID: 2403827
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients.
    Bennour A; Bellâaj H; Ben Youssef Y; Elloumi M; Khelif A; Saad A; Sennana H
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1329-36. PubMed ID: 21739181
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pathobiology of lymphoid and myeloid blast crisis and management issues.
    Ilaria RL
    Hematology Am Soc Hematol Educ Program; 2005; ():188-94. PubMed ID: 16304379
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
    Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB
    Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667
    [TBL] [Abstract][Full Text] [Related]  

  • 74. De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion.
    Hameed M; Alnoamani M; Marei M; Tailor I; Alshehri H; Tashkandi SA; Alswayyed A; Alrajhi AM; Zaidi SZA; Motabi I; AlShehry N; Alfayez M
    Hematology; 2022 Dec; 27(1):1259-1262. PubMed ID: 36448578
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia].
    Shi DY; Qin YZ; Lai YY; Shi HX; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):469-476. PubMed ID: 32654459
    [No Abstract]   [Full Text] [Related]  

  • 78. Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment.
    Morris CM
    Methods Mol Biol; 2011; 730():33-61. PubMed ID: 21431633
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.